The stock's rise snapped a three-day losing streak.

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

West Pharmaceutical Services (WST) stock was upgraded to Buy at Deutsche Bank due to an attractive entry point post-selloff. Read more here.

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

At its present level of around $200, WST stock is trading at just 5.1x trailing revenue, compared to its five-year average ...

West Pharmaceutical Services (WST) stock plummeted 38% on Thursday, making it the biggest decliner in the S&P 500. The sharp ...

Discover key insights from West Pharmaceutical Services' Q4 2024 earnings call, highlighting growth in GLP-1 elastomers, biologics, and HVP components.

The Global Vial Adaptors for Reconstitution Drug market is poised for substantial growth, reflecting strong financial projections and industry expansion. In 2023, the market was valued at USD 2,186.69 ...

"The addition of this five-partner team extends the capabilities of our 200-plus lawyer IP team," Morgan Lewis’ global IP ...

The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...

West Pharmaceutical Services Inc. closed 20.09% short of its 52-week high of $413.56, which the company reached on February ...